Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate starting-dose optimization for psoriasis
NL-OMON37246Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methotrexate in psoriasis, sponsored by Amsterdam University Medical Center. Primary endpoint: PASI 75 at week 16. Planned start Oct 2012; status: withdrawn.
02
Drugs
methotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON37246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37246.